Urinary protein profiles in ketorolac-associated acute kidney injury in patients undergoing orthopedic day surgery by Mariano, Filippo et al.
© 2017 Mariano et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. 
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work 
you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For 
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
International Journal of Nephrology and Renovascular Disease 2017:10 269–274
International Journal of Nephrology and Renovascular Disease Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
269
O R I G I N A L  R E S E A R C H
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/IJNRD.S137102
Urinary protein profiles in ketorolac-associated 
acute kidney injury in patients undergoing 
orthopedic day surgery
Filippo Mariano1 
Chiara Cogno1 
Fulvia Giaretta2,3 
Ilaria Deambrosis2,3 
Simona Pozza4 
Maurizio Berardino5 
Giuseppe Massazza6 
Luigi Biancone1,3
1Department of General and Specialist 
Medicine, Nephrology, Dialysis and 
Transplantation Unit, City of Health 
and Science, CTO Hospital, Turin, 
2Department of General and Specialist 
Medicine, Laboratory of Nephrology 
and Immunopathology,  City of Health 
and Science, Molinette Hospital, Turin, 
3Department of Medical Sciences, 
University of Turin, Turin, 4Department 
of Radiology and Radiotherapy, CTO 
Radiology, City of Health and Science, 
CTO Hospital, Turin, 5Department 
of Anesthesiology and Intensive 
Care, Anesthesiology and Intensive 
Care 5, City of Health and Science, 
CTO Hospital, Turin, 6Department of 
Orthopedics and Traumatology, Week 
Hospital Unit, City of Health and 
Science, CTO Hospital, and University 
of Turin, Turin, Italy
Background: Parenteral administration of ketorolac is very effective in controlling postoperative 
pain for orthopedic surgery. Ketorolac can induce clinically relevant renal alterations in elderly 
patients, whereas its short course is considered safe for young adults with normal preoperative 
renal function. In this study, of a cohort of young adults undergoing elective orthopedic day 
surgery,  we sought cases complicated by readmission due to acute kidney injury (AKI).
Patients and methods: Among 1397 young adults, aged 18–32 years who were admitted 
to undergo orthopedic day surgery from 2013 to 2015, four patients (0.29%, three males/one 
female) treated in postprocedure with ketorolac (from 60 to 90 mg/day for 1–2 days) were 
readmitted for suspected severe AKI. We evaluated functional outcome, urinary protein profiles 
and kidney biopsy (1 patient).
Results: After day surgery discharge, they experienced gastrointestinal disturbances, flank pain 
and fever. Readmitted on post-surgery days 3–4, they presented with oliguric AKI (creatinine 
range 158.4–466.4 µmol/L) and frank proteinuria (albumin range 2.1–6.0 g/L). Urine protein 
profiles demonstrated a nonselective glomerular proteinuria, with a significant 9.4-fold increase 
in glomerular/tubular index on day 6. Kidney biopsy on day 19 showed normal glomeruli and 
minimal tubular alterations and negative immunofluorescence. All patients recovered their renal 
function, and after 20 days proteinuria disappeared.
Conclusion: AKI can ensue even in young adults who have undergone a short course of 
ketorolac, when they suffered from relative dehydration, abdominal disturbances, flank pain and 
oliguria after discharge. Urine findings were characterized by a marked nonselective glomerular 
proteinuria disappearing in 2–3 weeks.
Keywords: ketorolac, acute kidney injury, glomerular tubular index, orthopedic day surgery
Introduction
Ketorolac is a widespread drug in the management of postoperative pain after a short-
stay elective orthopedic surgery.1 Parenteral administration is very effective, allowing 
a positive opioid-sparing effect.1,2
Apart from acute interstitial nephritis, an immunological reaction with defined his-
tological alterations, ketorolac can induce a continuum of renal functional alterations, 
changing from a frank picture of oliguric acute kidney injury (AKI) to some minor 
injuries, such as decreased renal plasma flow (RPF) and glomerular filtration rate (GFR), 
dysfunction in salt and water handling and in renin release by the juxtaglomerular 
apparatus.3,4 However, in adults with normal preoperative renal function, short course 
of ketorolac is considered safe, and not leading to postoperative AKI.4 In controlled 
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studies, 60 mg/day parenteral course of ketorolac for 2 days 
showed only a minimal decrease in potassium excretion,5 and 
only a transient reduction in renal function has been reported 
in young adults in the early postoperative period.4
In this article, we sought, in a cohort of young adults 
undergoing elective orthopedic day surgery, the cases com-
plicated by readmission due to AKI. We evaluated the renal 
functional alterations, the urinary protein profiles and in 1 
patient the renal histology.
Patients and methods
From 2013 to 2015, 6349 patients were admitted to undergo 
orthopedic day surgery at CTO Hospital. All these patients 
were ordinarily discharged within 48 hours. Among these 
patients, we sought the patients readmitted to hospital for any 
complication within 1 week. We retrieved 38 patients, and 
among those 4 patients (3 males/1 female, aged 18–32 years; 
Table 1) were readmitted for a severe picture of AKI. These 
4 AKI patients represented a 0.29% of 18–32-year-old 1397 
young adults.
All 4 patients had normal preoperative serum creati-
nine, and no previous history of renal disease. In addition, 
before surgery, all were classified in stage I–II American 
Society of Anesthesiology (ASA physical status classification 
system).6 According to the postprocedure antalgic protocol, 
they were treated with ketorolac (from 60 to 90 mg/day 
for 1–2 days), and other analgesic (paracetamol, tramadol; 
Table 1). On day 2, they were regularly discharged.
On the next day, at home they experienced vomiting (one 
case), nausea, epigastralgia, flank pain and fever (3 patients; 
Table 1), and they were readmitted on days 2–3.
During readmission stay, the 4 AKI patients were 
routinely monitored for urine output and blood pressure. 
Laboratory studies included urinalysis, 24-hour collection 
for urinary protein and albumin, complete blood counts, 
serum creatinine, urea, electrolytes, liver enzymes, albumin, 
immunological screening (complement fractions, antinuclear 
antibodies, immunoglobulin, anti-DNA) and urine samples 
for protein markers.
Urine sample study included urinary protein profiles by 
electrophoresis, and nephelometric quantification of spe-
cific glomerular (albumin, transferrin, immunoglobulin G, 
alpha-2-macroglobulin) and tubular (retinol-binding protein, 
alpha-1-microglobulin) marker proteins. Then, the analysis 
of marker proteins was performed by MDI-LABLINK 
software.7
Renal ultrasonography was performed for all patients.
All 4 patients were treated with intravenous (i.v.) crystal-
loids, furosemide and all other drugs when needed. As part 
of standard care, patient (case 1) underwent percutaneous 
kidney biopsy on day 19.
As to specific therapy, 3 out of 4 patients underwent a 
short course of corticosteroids (3 mg/kg/day of methylpred-
nisolone i.v. for 3 days).
Informed consent was given by the 4 patients whose case 
details are described in the study. They have provided written 
informed consent for the case details to be published.
Values were expressed as median (interquartiles).
Results
At readmission, all patients presented with signs of mild 
dehydration (median 3.2% of weight loss), 3 were oliguric 
and 1 anuric. No patient had symptoms or signs of allergy 
(rash, itching or eosinophilia). Biochemical data demon-
strated a picture of severe AKI, with increased creatinine 
(range 135.5–243.0 µmol/L).
Urine analysis showed frank albuminuria, in the absence 
of leukocyturia and/or microscopic hematuria. On the other 
hand, in 3 out of 4 patients, granular and cellular cast were 
occasionally present, with renal cells in case 1 (Table 1).
Renal ultrasonography revealed enlarged kidneys with 
hyperechogenic parenchyma.
Table 1 Clinical data of patients
Patient 
no.
Age 
(years)/
sex
Surgery ER access 
(days) 
Symptoms before 
AKI (T° peak C/day 
of peak)
Ketorolac 
(mg/day)/
therapy (days)
Other drugs  
(mg/day)
Urinary findings
1 27/M ACL surgery 3 Epigastralgia, flank 
pain, fever (39.3/third)
90/2 Paracetamol (3000), 
morphine (30)
Few renal cells, few 
granular casts, few cellular 
casts, some hyaline casts
2 18/F Malleol tibial 
fracture
4 Epigastralgia, fever 
(37.5/second) 
60/1 Tramadol (100) Few hyaline casts
3 31/M ACL + MCL 
surgery
4 Epigastralgia, flank pain 60/2 Paracetamol (4000), 
tramadol (200)
1 cellular cast, 1 granular 
cast, some hyaline casts
4 32/M ACL surgery 3 Flank pain, fever  
(37.5/second)
60/2 Paracetamol (3000), 
tramadol (100)
No significant alterations
Abbreviations: ACL, anterior cruciate ligament; AKI, acute kidney injury; ER, Emergency Room; MCL, medial collateral ligament.
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Immunological screening performed in the following days 
was within normal limits for all patients.
Creatinine maximally peaked in case 1 at 466.4 µmol/L 
on day 5 (Figure 1, upper left panel). Urine albumin (range 
2.1–6.0 g/L) decreased over days for all patients, whereas 
urine volume simultaneously increased (Figure 1). Total 
proteinuria median values were 1.60 (0.64–2.20), 0.68 
(0.45–0.90), 0.21 (0.16–0.26) and 0.26 (0.17–0.35) g/day 
(interquartiles) on days 6, 9, 12 and 18, respectively.
Analysis of marker proteins (MDI-LABLINK software)7 
demonstrated a nonselective glomerular type of proteinuria. 
On day 6, median glomerular/tubular index increased signifi-
cantly up to 9.4 times (Figure 2, lower panel), and albumin 
was the most part of proteinuria (Figure 2, upper panel). Pro-
teinuria, albuminuria and glomerular/tubular index returned 
to baseline after day 20 (Figure 2, upper and lower panel). 
Serum creatinine has decreased from 6 days onward for all 
4 patients (Figure 1).
Light microscopy on bioptic samples showed glomeruli 
with normal aspect and mostly normal tubular cells. However, 
only in few medullary and cortical tubules, accumulation of 
Tamm–Horsfall protein was seen within the lumen in associa-
tion with macrophages, some of which plurinucleated. Small 
caliber arterial vessels had small parietal hyaline plaques, 
while those of greater caliber showed discrete intimal fibrosis. 
Immunofluorescence studies were negative.
Discussion
Orthopedic day surgery patients treated with a short 
course of ketorolac and regularly discharged could be at 
risk of developing AKI when at home if they had present 
symptoms like fever, epigastralgia or bilateral flank pain. 
Ketorolac-associated AKI is a rare complication, but it 
can severely affect renal function and cause glomerular 
proteinuria.
Soon after its availability on the market in 1992, sev-
eral reports showed concerns about cases of postoperative 
ketorolac-associated AKI. However, in the following years, 
post-market experience and more information have demon-
strated the benefits of ketorolac in clinical practice, without 
a clear evidence on an additive risk in postoperative AKI.4,8 
A wide retrospective cohort of patients including over 10,000 
courses of ketorolac for 2 days in 35 hospitals evaluated the 
AKI incidence in post-surgery. It showed an AKI incidence 
value as low as 1.1% for treated ketorolac patients. Of more, 
a comparison for the risk of AKI between parenteral ketorolac 
and opioids showed no significant difference.8,9 In that report,9 
AKI was defined as a peak serum creatinine concentration 
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Figure 1 Pattern of plasma creatinine (mmol/L), urine albumin (g/L) and urine volume (L/day) for each of the 4 studied patients (A–D).
Note: Data are shown over the first 20 days after surgical procedure.
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50% greater than the baseline value, or a notation in the 
hospital chart that acute renal failure had occurred during 
the course of analgesic therapy.9
In our experience, the incidence of reported AKI was as 
low as 0.29%. However, our patients were different, as they 
were healthy and young adults, without any known preop-
erative risk factors for AKI,3,5 and not in ordinary admission 
but in day surgery. In effects, after day surgery discharge, 
all patients reported to have had abdominal symptoms such 
as epigastralgia, bilateral flank pain, nausea, vomiting and 
fever (Table 1). Abdominal symptoms were likely due to 
gastrointestinal toxicity of ketorolac itself. As for fever, 
early postoperative pyrexia is a phenomenon often associated 
with knee surgery. It is believed to be due to surgical trauma 
and sustained by local and systemic release of endogenous 
proinflammatory mediators (complement products, IL-1β, 
IL-6 and TNF-α).10 In our patients, both gastrointestinal 
disturbances and fever could result in a loss, and/or inad-
equate consumption of fluids. All these factors favored an 
underlying volume depletion and reduced renal perfusion. As 
patients kept taking ketorolac, the inhibition of prostaglandin 
synthesis could cause a deep and prolonged renal ischemia, 
resulting in oliguric AKI.3–5 Interestingly, in subjects very 
susceptible to dehydration such as children, AKI onset has 
also been described after nonsteroidal anti-inflammatory drug 
(NSAID) administration taken for fever due to gastroenteritis, 
or infectious diseases,11 or for headache, dysmenorrhea and 
suicidal attempt.12
In the first days, we found a marked proteinuria, of glo-
merular type and nonselective. After 9–12 days, glomerular 
Figure 2 Protein/creatinine ratio and glomerular–tubular index over the first 20 days.
Note: Upper panel shows an early marked increase in proteinuria and albuminuria, which decreased over days. Lower panel shows the pattern of glomerular/tubular index, 
which increased 9.4-fold on day 6, then decreased until its normalization on day 20. Insert: urinary marker patterns of case 1 on day 6. The protein markers such as α2-MG, 
IgG, Trf, Alb, α1-MG, RbP are represented by different columns distributed according to their molecular weight, and grouped in glomerular and tubular markers. Increased 
values (gray bars) are expressed as multiple of the upper reference limit (black bars). Glomerular/tubular index results from the ratio between relative increase in glomerular 
proteins and relative increase in tubular proteins.7
Abbreviations: Alb, albumin; α1-MG, alpha-1-macroglobulin; α2-MG, alpha-2-macroglobulin; IgG, immunoglobulin G; RbP, retinol-binding protein; Trf, transferrin.
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proteinuria disappeared leaving a minor tubular component. 
Proteinuria reflected an increased glomerular permeability, 
likely due to generation of inflammatory mediators triggered 
by the initial ketorolac-induced ischemic injury. In effects, 
at admission, all patients experienced bilateral flank pain, 
and ultrasonography revealed enlarged kidneys. In humans, 
the target enzymes of ketorolac, COX-1 and COX-2, are 
present in parenchymal kidney cells, including podocytes, 
mesangial, macula densa and cortical thick ascending limb 
cells.13 COX inhibitors such as ketorolac can induce renal 
phlogosis by a number of different mechanisms, such as 
a shunt of arachidonic acid from COX to LOX pathway 
with an exaggerated synthesis of peptidoleukotrienes LTD4 
capable of preglomerular vasoconstrictor activity,3–5,14 or 
a block of specific enzymes that inactivate leukotrienes.14 
Of more, in a sheep model of NSAID-associated AKI with 
proteinuria and increased creatinine, protein leakage in the 
glomeruli was associated with activation of complement 
cascade pathway in urine,15 which in turn amplified the 
injury on tubular cells via inflammatory and fibrinogenic 
pathways.16
As an outcome, all 4 patients fully recovered renal func-
tions in 3–6 weeks. This favorable outcome is consistent 
with no significant histological alterations on kidney biopsy 
19 days after the kidney injury.
Conclusion
Reported data show that ketorolac-associated AKI is a rare, 
but severe early complication. It can ensue even after a short 
course of ketorolac in young adult patients, when they suffer 
from dehydration after discharge. This form of AKI was char-
acterized by a marked nonselective glomerular proteinuria 
with a minor tubular component.
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